Advanced

Evaluation of intra- and extracellular activity of trimethoprim-sulfamethoxazole against susceptible and multidrug-resistant Mycobacterium tuberculosis.

Davies Forsman, L; Schön, T; Simonsson, U S H; Bruchfeld, J; Larsson, M; Juréen, P; Sturegård, Erik LU ; Giske, C G and Angeby, K (2014) In Antimicrobial Agents and Chemotherapy 58(12). p.7557-7559
Abstract
We investigated the activity of trimethoprim-sulfamethoxazole (SXT) against Mycobacterium tuberculosis. The MIC distribution of SXT was 0.125/2.4-2/38 mg/L for the 100 isolates tested, including multi- and extensively drug-resistant isolates (MDR/XDR-TB), whereas the intracellular MIC90 of sulfamethoxazole (SMX) for H37Rv was 76 mg/L. In an exploratory analysis using fAUC0-24h/MIC ≥25 as a potential target, the cumulative fraction response was ≥90% at doses ≥2400 mg of SMX. SXT is a potential treatment option for MDR/XDR-TB.
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Antimicrobial Agents and Chemotherapy
volume
58
issue
12
pages
7557 - 7559
publisher
American Society for Microbiology
external identifiers
  • pmid:25246405
  • wos:000345221000065
  • scopus:84912120697
ISSN
1098-6596
DOI
10.1128/AAC.02995-14
language
English
LU publication?
yes
id
0517dd7a-b403-4386-b2ec-86c1d1b575cb (old id 4691052)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/25246405?dopt=Abstract
date added to LUP
2014-10-08 15:39:43
date last changed
2017-08-27 03:25:12
@article{0517dd7a-b403-4386-b2ec-86c1d1b575cb,
  abstract     = {We investigated the activity of trimethoprim-sulfamethoxazole (SXT) against Mycobacterium tuberculosis. The MIC distribution of SXT was 0.125/2.4-2/38 mg/L for the 100 isolates tested, including multi- and extensively drug-resistant isolates (MDR/XDR-TB), whereas the intracellular MIC90 of sulfamethoxazole (SMX) for H37Rv was 76 mg/L. In an exploratory analysis using fAUC0-24h/MIC ≥25 as a potential target, the cumulative fraction response was ≥90% at doses ≥2400 mg of SMX. SXT is a potential treatment option for MDR/XDR-TB.},
  author       = {Davies Forsman, L and Schön, T and Simonsson, U S H and Bruchfeld, J and Larsson, M and Juréen, P and Sturegård, Erik and Giske, C G and Angeby, K},
  issn         = {1098-6596},
  language     = {eng},
  number       = {12},
  pages        = {7557--7559},
  publisher    = {American Society for Microbiology},
  series       = {Antimicrobial Agents and Chemotherapy},
  title        = {Evaluation of intra- and extracellular activity of trimethoprim-sulfamethoxazole against susceptible and multidrug-resistant Mycobacterium tuberculosis.},
  url          = {http://dx.doi.org/10.1128/AAC.02995-14},
  volume       = {58},
  year         = {2014},
}